NCT00174616 - CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Rectal Neoplasms

Interventions

DRUG

Oxaliplatin, capecitabine, radiotherapy

"* Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"

Trial Locations (7)

Unknown

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Frankfurt

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Pe Gouda

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford Surrey